iPharma of Hong Kong in-licensed global rights from Boehringer Ingelheim to manufacture, develop, and commercialize BI 853520, a focal adhesion kinase inhibitor (FAKi) aimed at solid tumor cancers. iPharma is a joint venture between i-Bridge Capital, a China pharma investor, and BioLineRx, an Israeli biopharma. iPharma plans to start Phase I/II studies of BI 853520 in 2018 in combination with immune checkpoint inhibitors and/or potentially other therapies. iPharma will make an undisclosed upfront payment, plus pay milestones and royalties, though details were not disclosed.
Source: China Biotoday
